Abstract | GABA A (γ-aminobutyric acid, type A) receptors are a family of ligand-gated ion channels that are essential for the regulation of central nervous system function. Benzodiazepines -which non-selectively target GABA A receptors containing the α1, α2, α3 or α5 subunits -have been in clinical use for decades and are still among the most widely prescribed drugs for the treatment of insomnia and anxiety disorders. However, their use is limited by side effects and the risk of drug dependence. In the past decade, the identification of separable key functions of GABA A receptor subtypes suggests that receptor subtype-selective compounds could overcome the limitations of classical benzodiazepines; furthermore, they might be valuable for novel indications such as chronic pain, depression, schizophrenia, cognitive enhancement and stroke.
GABA A (γ-aminobutyric acid, type A) receptors are the molecular targets of benzodiazepines. In this Review, we provide an overview of the advances in our understanding of the physiological and pharmacological roles of GABA A receptor subtypes, their potential applications in drug development and an update on the clinical development of GABA A receptor subtype-selective compounds, thus complementing other more historically oriented 1, 2 or specialized 3-7 reviews. The term benzodiazepine refers to a chemical structure that consists of a fusion of a benzene ring and a diazepine ring, in which the two N atoms are usually located in positions 1 and 4. In the 1950s, it was discovered by serendipity that benzodiazepines have various therapeutically useful actions, including anxiolysis, sedation, seizure suppression and muscle relaxation. As sedative-hypnotic (sleep-inducing) drugs, they have essentially replaced the barbiturates owing to a substantially improved therapeutic index. Benzodiazepines mediate their actions via a modulatory binding site (the benzodiazepine binding site (BZ site)) that is present on most (although not all) GABA A receptors 8
. Unlike barbiturates, GABA A receptor modulation by BZ-site agonists is self-limiting: the conductance of the channel in the presence of GABA and benzodiazepines is not higher than the conductance that can be achieved with high concentrations of GABA alone. Also in contrast to barbiturates, benzodiazepines do not open the chloride channel in the absence of GABA. One of the limitations of current benzodiazepines is that the pharmacological effects cited above are not clearly separable by dosing. For example, although the anxiolytic actions are observed at lower doses than the sedative actions, sedation is still a problem if benzodiazepines are used as daytime anxiolytics, and therefore the development of novel anxioselective, non-sedating compounds is desirable. Furthermore, benzodiazepines have addictive properties and are liable to be abused, which limits their long-term use. In addition to the development of addiction, physical dependence and tolerance are areas of concern.
Benzodiazepines have been shown to bind to specific sites in the central nervous system 9, 10 , which later turned out to be modulatory sites on the GABA A receptor
. The functions of individual GABA A receptor subtypes have been elucidated mainly in genetically modified mice in which individual GABA A receptor α subunits have been rendered insensitive to diazepam. Histidineto-arginine point mutations at a conserved residue in the α1, α2, α3 or α5 subunit abolish binding of diazepam, whereas the action of the physiological neurotransmitter GABA is preserved [11] [12] [13] [14] 
. In α1(H101R) mice (mice in which histidine at position 101 of the α1 subunit has been substituted for arginine), the sedative action and anterograde amnestic action of diazepam were absent and its anticonvulsant action was reduced, but its anxiolytic-like action was present 11 . In α2(H101R) mice, the anxiolytic-like action of diazepam was absent and its myorelaxant action (which is observed at higher doses than the anxiolytic-like action) was reduced, whereas the sedative action was present 13, 15 . In α3(H126R) mice and in α5(H105R) mice, the myorelaxant action of diazepam was reduced, whereas sedative and anxiolytic-like actions were present [13] [14] [15] . These experiments demonstrated that the sedative, anterograde, amnestic and partly the anticonvulsant actions of diazepam are mediated by α1-containing GABA A receptors; the anxiolytic-like and, to a large extent, the myorelaxant actions are mediated by α2-containing GABA A receptors; and the myorelaxant action is mediated in part by α3-and α5-containing GABA A receptors. Moreover, the development of tolerance to the sedative action of benzodiazepines has been linked to α5-containing GABA A receptors 16 , and their addictive properties have been linked to α1-containing GABA A receptors 17 .
Although experiments with the histidine-to-arginine mutated mouse lines clearly define a role for the mutated GABA A receptor α subunit if a response to diazepam is absent, they do not formally exclude a contribution of other α subunits to the response in question. For example, the observation that diazepam does not sedate α1(H101R) mice indicates that diazepam does not have a sedative effect via α2-, α3-and α5-containing GABA A Box 1 | GABA A receptors GABA A (γ-aminobutyric acid, type A) receptors are heteropentamers made up from 19 known subunits (α1-6, β1-3, γ1-3, δ, ε, θ, π and ρ1-3) 18, 87 with an integral channel that is permeable to Cl -ions (see the figure, part a). It is noteworthy that homopentameric ρ receptors are insensitive to bicuculline and baclofen and have been referred to as GABA C receptors 88 ; however, the Nomenclature Committee of the International Union of Pharmacology (IUPHAR) does not recommend this nomenclature 87 . GABA-induced chloride influx hyperpolarizes the postsynaptic neurons. Many GABA A receptors contain two α subunits, two β subunits and one γ subunit with two GABA binding sites formed by α and β subunits (see part a of the figure). The binding site for benzodiazepines is formed by one of the α subunits (α1, α2, α3 or α5) and a γ subunit (typically the γ2 subunit, which is present in approximately 90% of GABA A receptors). GABA A receptors containing the α4 or α6 subunit do not bind clinically used classical benzodiazepines. Histidine to arginine mutations at a conserved residue in the α subunits functionally abolish the benzodiazepine binding site (BZ site).
Approximately 60% of all GABA A receptors have the subunit combination α1β2γ2, approximately 15-20% have the α2β3γ2 combination, approximately 10-15% have the α3βnγ2 combination, approximately 5% have the α4βnγ or α4βnδ, combination, less than 5% have the α5β2γ2 combination and, likewise, less than 5% have the α6β2/3γ2 combination 89 . It is noteworthy that some GABA A receptors may also contain two different α subunits 90 . In recombinant receptors, the α subunit adjacent to the γ2 subunit determines the sensitivity to benzodiazepines 91 . In addition to benzodiazepines, the GABA A receptor is the major target for the clinically used hypnotic drugs zolpidem, zopiclone, (S)-zopiclone and zaleplone, for barbiturates and for many general anaesthetics 92 . GABA A receptors are a major target for the actions of the clinically used intravenous anaesthetics etomidate and propofol, and β3(N265M) mice cannot be immobilized using these drugs, suggesting an essential role of β3-containing GABA A receptors for immobilization 93 . Clinically used volatile anaesthetics such as isoflurane, enflurane and sevoflurane presumably act via a multitude of targets, GABA A receptors being only one of them. Their contribution to the immobilizing action of volatile anaesthetics is limited [93] [94] [95] . GABA A receptor-mediated events have two effects on the postsynaptic membrane: an increase of the postsynaptic membrane conductance (shunting inhibition) and a change in the membrane potential owing to movement of Cl -ions through the membrane (hyperpolarizing inhibition). Synaptic receptors that detect millimolar concentrations of GABA mediate fast inhibitory postsynaptic potentials (IPSPs), whereas extrasynaptic receptors that detect micromolar concentrations of GABA mediate slower IPSPs and also tonic conductances (see part b of the figure). Tonic and phasic conductances underlie different physiological and behavioural processes.
Human mutations in GABA A receptor subunits Although GABAergic agents have been used to treat various disorders, only a limited number of mutations have been found in GABA A receptor subunit genes. These include point mutations in the α1 and γ2 subunits in patients with genetic epilepsies 96 . Genetic association studies indicate single nucleotide polymorphisms (SNPs) in the gene encoding the α2 subunit in alcohol dependence 97, 98 and illicit drug dependence [99] [100] [101] . However, the functional consequences of this genomic variation are not fully understood. Furthermore, the gene encoding the β1 subunit of the GABA A receptor has been linked to alcohol dependence 102 and also to bipolar disorder 103 . Association signals have also been detected for the genes encoding the α4, α5, β3 and ρ1 subunits 103 . The genes encoding the α1, α6, β2 and π subunits have been linked to schizophrenia 104 . receptors; however, this does not exclude the possibility that one of the three diazepam-sensitive α subunits in these mice may have a sedative effect and another one may have a stimulant effect, so they cancel each other out. In the past decade, important advances in the understanding of the functions of GABA A receptor subtypes have been made. Particular GABA A receptor subtypes have been identified as potential therapeutic targets and some of them have been linked to unwanted side effects and should therefore be avoided. Accordingly, drug discovery has been directed towards identifying compounds that do not interact with these receptor subtypes. This was achieved either by binding selectivity or by selective modulation at a given receptor subtype (BOX 2) .
In this Review, we provide a brief summary of the structure and function of GABA A receptors and discuss recent progress in drug development efforts to address the sedative side effects and addictive properties of classical benzodiazepines using GABA A receptor subtypeselective compounds. Finally, we highlight the emerging potential of such compounds in novel indications, including psychiatric disorders.
Box 2 | Binding and functional selectivity
Ligands at the benzodiazepine binding site (BZ site) of the GABA A (γ-aminobutyric acid, type A) receptor are allosteric modulators. They modify the efficacy and/or affinity of agonists (for example, GABA) and thus regulate their activity. The direction of the modulation can be positive, negative or neutral, and is achieved by stabilizing different conformations of the receptor. Allosteric modulators of the GABA A receptor are frequently referred to as BZ site agonists or BZ site inverse agonists, in part because it was originally assumed that the BZ site is an independent receptor 9, 105 . More precisely, they might be referred to as positive allosteric modulators or negative allosteric modulators, respectively. Prototypic ligands for a positive allosteric modulator, a negative allosteric modulator and a BZ site antagonist are diazepam, β-CCM (methyl β-carboline-3-carboxylate) and flumazenil (Ro 15-1788), respectively.
Selectivity of a ligand for a specific GABA A receptor subtype can be obtained either by affinity (by forming or not forming a receptor-ligand complex) or efficacy (by eliciting or not eliciting a biological response after binding to the receptor). These two properties define its potency profile. As binding experiments cannot reveal the full potency profile of a ligand, subtype selectivity is also assessed in electrophysiological experiments performed with, for example, human embryonic kidney 293 cells or Xenopus laevis oocytes heterologously expressing GABA A receptor subtypes (FIG. 3a) . The affinity-selective positive allosteric modulator (agonist) represented in part a of the figure has different affinities for the red, green, blue and yellow receptor subtypes (shifts in the concentration-response curves). The efficacy-selective agonist in part b of the figure has the same affinities for all receptor subtypes (no shifts in the concentration-response curves).
However, its maximum efficacy at the red receptor subtype is much higher than that at the other receptor subtypes. Although these agonists have very different potency profiles, at a given therapeutic concentration (30 nM, vertical arrows in a and b) their efficacies measured at the different receptor subtypes are similar. This also holds true for the affinity-selective (part c) and efficacy-selective (part d) negative allosteric modulators (inverse agonists). 18, 19 . There is much greater diversity in the GABA A receptor system (which has 19 known subunit genes) than in the GABA B receptor system (which only has three known subunit genes). Both classes of GABA receptors modulate emotions, cognition, pain and muscle tone and are targets of clinically used drugs. GABA A receptors are allosterically modulated by benzodiazepines, which are used for their sedative, anxiolytic, anticonvulsant and muscle relaxant actions. Baclofen, which is an agonist at the GABA B receptor, is used to relieve muscle spasticity.
Benzodiazepines have sedative-hypnotic properties. Although these properties are useful for the treatment of insomnia, they are undesirable side effects when benzodiazepines are used for most other purposes -for example, for daytime anxiolysis. Sedative effects are a major obstacle for the use of ligands that target the BZ site for novel therapeutic indications. For indications other than insomnia, it is thus important to identify -and avoid -the receptor subtype (or subtypes) that mediate the sedative action of benzodiazepines.
In addition to benzodiazepines, other compounds have been developed that either bind to the same site as benzodiazepines or bind to an overlapping site. Zolpidem, which is an imidazopyridine, has a high affinity for α1-containing GABA A receptors, a 20-fold lower affinity for α2-containing GABA A receptors and α3-containing GABA A receptors, and no affinity for α5-containing GABA A receptors 20 , and is therefore frequently referred to as being α1-selective. It is used clinically for the treatment of insomnia. This suggests that α1-containing GABA A receptors are important targets for the sedative-hypnotic action of zolpidem. Indeed, in α1(H101R) mice the motor sedative action of zolpidem was abolished, which demonstrates that the sedative action of zolpidem is mediated by α1-containing GABA A receptors 21 . In α1(H101R) mice, diazepam increases sleep continuity -that is, it reduces the number of brief awakenings derived from electroencephalography (EEG) recordings -whereas its motor sedative effect is absent, which indicates that motor sedation is mediated by α1-containing GABA A receptors, but enhancement of sleep continuity occurs independently of α1-containing GABA A receptors 22 . The significance of this finding for the design of hypnotic drugs is currently unclear.
The GABA analogue gaboxadol (FIG. 2a) acts at the GABA site of the GABA A receptors. In mice, it induces sedation largely via α4-containing GABA A receptors 23 , but the development of this compound was stopped in 2007 when Phase III trials revealed unexpected side effects, including hallucinations and disorientation.
Reduction of sedative effects
The development of non-sedating benzodiazepine anxiolytics was unsuccessful for decades, at least in part because it was unknown whether the sedative-hypnotic and anxiolytic actions are pharmacologically separable. After identifying which GABA A receptor subtype (or subtypes) mediates these actions, selective compounds have to be screened and optimized. Selectivity can be achieved at the level of binding and at the level of efficacy
. Initial screens for binding-selective compounds were unsuccessful, but useful efficacy-selective (that is, functionally selective) compounds have been identified.
As described above, α2-containing GABA A receptors have been found to mediate the anxiolytic-like action of diazepam 13 , whereas α1-containing GABA A receptors mediate the sedative action of diazepam 11, 12 . Thus, one would predict that a compound that is selective for α2-containing GABA A receptors and has no activity at α1-containing GABA A receptors would be a nonsedating anxiolytic. The contribution of α3-containing GABA A receptors to anxiolysis is less clear and more controversial. Although experiments involving point mutations in mice are consistent with the view that α3-containing GABA A receptors are neither required nor sufficient for anxiolysis 13 , the experimental compound TP003 (FIG. 2a) , which has been described to have a selective efficacy at recombinant α3-containing GABA A receptors in vitro, is anxiolytic in the elevated plus maze test in rats 24 and in a conflict test in monkeys 25 , in which it also lacked the hyperphagic effect of non-selective benzodiazepines 25 . However, the selectivity of TP003 for α3-containing GABA A receptors has not yet been demonstrated in vivo.
L-838417 (FIG. 2a) , which is a partial positive allosteric modulator (partial agonist) at α2-, α3-and α5-containing GABA A receptors and an antagonist at α1-containing GABA A receptors 12 (FIG. 3b) , displays a pharmacological profile as a non-sedating anxiolytic drug in mice 12 and primates 26 . However, unfavourable pharmacokinetic properties have precluded further development of this compound 27 . TPA023 (also known as MK-0777) (FIG. 2a) , which is an α2/α3-selective positive allosteric modulator, has also been demonstrated to have anxiolytic but not sedative effects in rodents 28 ; TPA023 is a partial agonist that has 0% efficacy at α1-containing GABA A receptors, 11% efficacy at α2-containing GABA A receptors, 21% efficacy at α3-containing GABA A receptors and 5% efficacy at α5-containing GABA A receptors, compared with chlordiazepoxide. TPA023 was evaluated in three separate Phase II studies in generalized anxiety disorder. These studies were terminated early owing to preclinical toxicity (cataract formation) in long-term dosing studies 2 , therefore there were not enough data available for within-trial comparisons 4 . Combining the data from these separate studies revealed that TPA023 provided a considerably greater reduction of the Hamilton Anxiety Rating Scale (HAM-A) score relative to baseline, which was consistent with TPA023 having anxiolytic-like activity 4 . As TPA023 did not have sedative effects in these Phase II trials even at a receptor occupancy of >50% 4 -an occupancy at which diazepam has sedative effects in mice 29 -these data provide proof-of-principle that non-sedating anxiolysis can be achieved in humans by targeting the α2-and α3-containing GABA A receptor subtypes.
Another experimental compound, ocinaplon (DOV-273547) (FIG. 2a) , had anxiolytic but not sedative effects in rodents and in humans, as demonstrated in Phase I and Phase II studies with 127 and 60 patients, respectively 30, 31 . Surprisingly, however, in recombinant receptors expressed in Xenopus laevis oocytes, it modulated α1-, α2-, α3-and α5-containing GABA A receptors without showing subtype specificity 30 . The reason for this discrepancy between in vitro electrophysiological data obtained with recombinant receptors and in vivo observations is currently unknown. Ocinaplon was not developed further owing to hepatic toxicity issues, but it can be viewed as proof-of-principle that it is possible to develop non-sedating anxiolytic drugs by targeting the GABA A receptor.
MRK-409 (also known as MK-0343) (FIG. 2a) , which is structurally related to TPA023 and L-838417, is a positive allosteric modulator (agonist) with higher efficacy at α3-containing GABA A receptors but no binding selectivity. Its efficacy is 18% at α1-containing GABA A receptors, 23% at α2-containing GABA A receptors, 45% at α3-containing GABA A receptors and 18% at α5-containing GABA A receptors, compared with chlordiazepoxide 32 . MRK-409 displayed an anxioselective profile in rats and primates but produced sedation in humans at low levels of receptor occupancy (<10%) 4 . This indicates that although a low efficacy at α1-containing GABA A receptors may not have an overtly sedative effect in rodents or primates, it apparently induces sedation in humans, and therefore even a small residual efficacy at α1-containing GABA A receptors should raise caution 32 . This also demonstrates that experiments with rodents and primates may not always predict accurately whether a compound has sedative effects in humans. Another high-affinity compound, TPA023B (FIG. 2a) , which -like MRK-409 -is an agonist at the α2-containing GABA A receptors, α3-containing GABA A receptors and α5-containing GABA A receptors but is an antagonist at the α1-containing GABA A receptor, was well-tolerated in humans 33 .
Reduction of abuse potential
In a community-based study of benzodiazepine prescription patterns, only 1.6% of patients receiving benzodiazepine prescriptions had prescriptions for long time periods with high doses, indicating an abuse of or a dependence on benzodiazepines 34 . However, in alcohol-and drug-dependent outpatients, benzodiazepine dependence was found to be prevalent 35 . It has been estimated that approximately 0.1-0.2% of the adult population abuse or are dependent upon benzodiazepines 34 , which might translate into approximately 300,000-600,000 people in the United States, highlighting the need for novel compounds with a reduced potential for addiction.
All addictive drugs increase dopamine levels in the mesolimbic dopamine system 36 , and it has been suggested that addictive drugs hijack the reward system. Benzodiazepines increase the firing of dopaminergic neurons in the ventral tegmental area (VTA) by decreasing the activity of GABAergic interneurons (FIG. 4) . Dopaminergic neurons in the VTA express α3-containing GABA A receptors; by contrast, the GABAergic interneurons in the VTA express α1-containing GABA A receptors 17 . Benzodiazepines inhibit the interneurons via their α1-containing GABA A receptors, which results in disinhibition of the dopaminergic neurons. Unselective benzodiazepines also modulate the α3-containing GABA A receptors on dopaminergic neurons in the VTA, but the disinhibition via α1-containing GABA A receptors on interneurons seems to be the predominant effect. This disinhibition triggers drug-evoked synaptic plasticity in excitatory glutamatergic afferents that form synapses with dopaminergic neurons in the VTA and underlies drug reinforcements 17, 37 . In mice, even a single dose of benzodiazepines has been shown to elicit such neuroplastic changes 37 .
In α1(H101R) mice, the disinhibition is absent, clearly demonstrating a crucial role of α1-containing GABA A receptors 17 . Furthermore, in an oral selfadministration experiment, wild-type mice and α3(H126R) mice preferred midazolam, whereas α1(H101R) mice showed no preference for midazolam, indicating that α1-containing GABA A receptors are essential for midazolam self-administration 17 . Thus, subunit-selective benzodiazepines that do not positively modulate α1-containing GABA A receptors may be less addictive. In self-administration experiments with rhesus monkeys under a progressive ratio schedule of intravenous drug delivery, the breakpoint (that is, the highest response requirement completed, a measure of how hard an animal worked to obtain the drug) was higher for zolpidem, midazolam and diazepam, which all modulate α1-containing GABA A receptors, than for L-838417, which is an antagonist at α1-containing GABA A receptors and a partial agonist at α2-, α3-and α5-containing GABA A receptors 26 . This finding is consistent with the idea that α1-containing GABA A receptors play an important part in the addictive properties of benzodiazepines. Furthermore, in self-administration experiments in baboons, a withdrawal syndrome was observed following cessation of TPA123 self-administration (this compound displays 23% efficacy at α1-containing GABA A receptors, 35% efficacy at α2-containing GABA A receptors, 43% efficacy at α3-containing GABA A receptors and 19% efficacy at α5-containing GABA A receptors when compared with chlordiazepoxide) 38 (FIG. 2a) . In contrast to TPA123, only a mild withdrawal syndrome developed following cessation of self-administration of TPA023, which has no efficacy at α1-containing GABA A receptors (but 11% efficacy at α2-containing GABA A receptors, 21% efficacy at α3-containing GABA A receptors and 5% efficacy at α5-containing GABA A receptors when compared with chlordiazepoxide) 38 . These findings are consistent with an important role of α1-containing GABA A receptors for reinforcement. However, it cannot be ruled out at this point that the differences in reinforcement are due to differences in efficacy at α2-, α3-or α5-containing GABA A receptors.
Novel therapeutic indications
Recently gained knowledge on the physiological and pharmacological functions of GABA A receptor subtypes has made it possible to target GABA A receptor subtypes for indications that are unrelated to the current uses of benzodiazepines. For these indications, the use of subtype-selective allosteric modulators acting via the BZ site represents a novel approach compared with currently established pharmacological therapies.
Analgesia. Benzodiazepines are generally not considered to be analgesic agents as they lack clear efficacy when given systemically in humans 39 . In particular, sedative actions have been found to limit the usefulness of GABAergic agents as analgesics 39 , although this limitation can be overcome experimentally by administering the drugs intrathecally. Central GABA A receptors, such GABA (γ-aminobutyric acid) is applied to a cell expressing a GABA A (GABA type A) receptor subtype for the time indicated by the black horizontal bar, resulting in a current symbolized by the blue trace (a). When GABA is applied in the presence of a positive allosteric modulator (PAM; a benzodiazepine binding site (BZ site) agonist), the current is enhanced (orange trace). Negative allosteric modulators (NAMs; BZ site inverse agonists) and neutral allosteric modulators (BZ site antagonists) either decrease (green trace) or have no effect (red trace), respectively, on the GABA-induced current. A subtype-selective modulation of the current is observed when GABA is applied in the presence of L-838417 (b) or RO4938581 (c) to cells expressing various GABA A receptors. The percentage modulation of GABA-induced chloride currents is shown. The lack of modulation of α1-containing GABA A receptors by L-838417 is thought to be the basis for the lack of a sedative action of this compound in animals, whereas its partial positive allosteric modulatory (agonistic) action at α2-containing GABA A receptors (and potentially α3-containing GABA A receptors) is thought to be responsible for its anxiolytic-like action. Similarly, the lack of modulation of α1-containing GABA A receptors by RO4938581 is thought to be -at least in part -the basis for the lack of a pro-convulsive potential of this drug; the cognition-enhancing effects are hypothesized to be mediated via its negative allosteric modulation (inverse agonism) at α5-containing GABA A receptors. These illustrative traces are based on data in REFS 12,78. 
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as those in the periaqueductal grey (PAG), an area known to be involved in the regulation of descending antinociceptive tracts, are pro-nociceptive at supraspinal sites 40 . By contrast, GABA A receptors in the spinal cord have antihyperalgesic actions 3 . When diazepam is administered intrathecally in α2(H101R) and α3(H126R) mice, its antihyperalgesic action is significantly reduced in models of inflammatory pain and of neuropathic pain, demonstrating that spinal α2-and α3-containing GABA A receptors are mediating the antihyperalgesic actions of intrathecal diazepam 41 . Studies in α5(H105R) mice showed a minor role for spinal α5-containing GABA A receptors in a model of inflammatory pain 41 , and systemically applied L-838417 has an antihyperalgesic action in wild-type rats in models of inflammatory and neuropathic pain 41 . As mentioned previously, L-838417 is an α2-, α3-and α5-partial agonist and an α1-antagonist 12 . As α2, α3 and α5 subunits are the predominant α subunits in the spinal cord and the PAG predominantly expresses the α1 subunit 42 , L-838417 is likely to positively modulate antihyperalgesic spinal GABA A receptors while blocking central pro-algesic GABA A receptors. Potentially, both actions contribute to its antihyperalgesic effects. Interestingly, functional magnetic resonance imaging (fMRI) in rats demonstrated that L-838417 (after stimulation of an inflamed hind paw with noxious heat) reduced the activity of brain areas related to the sensory and associative-emotional components of pain, such as the medial thalamus, contralateral primary sensory cortex, cingulate cortex, frontal association cortex and limbic system (including the amygdala, entorhinal cortex and hippocampus) 41 . Furthermore, in contrast to morphine, over a 10-day treatment period no tolerance develops to L-838417 (REF. 41 ).
These findings suggest that α2/α3-selective or α2/ α3/α5-selective agonists may represent a novel class of analgesic drugs that could be used in conditions associated with inflammatory pain or with neuropathic pain, either alone or in combination with existing analgesics. There is an overlap between pain and emotion-reward-motivation brain circuitry; psychiatric disorders are commonly associated with alterations in pain processing and chronic pain may impair emotional and neurocognitive functions 43 . Thus, the dual actions of α2/α3-selective agonists on emotions and pain may be particularly useful therapeutically.
The compound NS11394 (FIG. 2a) is a partial agonist with a functional selectivity profile for α5-containing GABA A receptors. The maximal potentiation of NS11394 relative to diazepam is 78% at α5-containing GABA A receptors, 56% at α3-containing GABA A receptors, 22% at α2-containing GABA A receptors and 7.8% at α1-containing GABA A receptors. NS11394 is antihyperalgesic in rat models of inflammatory and neuropathic pain 44 , as well as anxiolytic and only minimally sedative 45 . Likewise, the compound HZ-166, a partial agonist with selectivity for α2-and α3-containing GABA A receptors, had antihyperalgesic action in mouse models of neuropathic and inflammatory pain 46 . At doses producing maximal antihyperalgesia, HZ-166 did not induce sedation and motor impairment 46 . Furthermore, there was no development of tolerance over a 9-day chronic treatment period 46 . TPA023, an α2/α3-selective partial agonist that is anxiolytic in humans, attenuated formalin-induced nocifensive behaviour in a similar way to NS113934, and both compounds reversed hind paw mechanical hypersensitivity and weight-bearing deficits in carageenan-inflamed and nerve-injured rats 47 . Diazepam was ineffective in these models.
It has recently been shown that partial negative allosteric modulators (partial inverse agonists), such as the non-selective FG-7142 and the α5-selective α5IA-II, also display antihyperalgesic actions in models of inflammatory and/or neuropathic pain 47 . The reasons for this are currently unclear. In any case, the results with NS11394, TPA023 and HZ-166 in rodents provide independent evidence for the potential usefulness of α1-sparing compounds as antihyperalgesic agents. It remains to be determined whether such effects will also be observed in humans. GABA (γ-aminobutyric acid)-ergic neurons in the ventral tegmental area (VTA) express the α1 subunit, whereas dopaminergic neurons in the VTA predominantly express the α3 subunit. Binding of benzodiazepines to the α1-containing GABA A (GABA type A) receptors on GABAergic VTA neurons leads to a reduction of the activity of these cells, and thus reduced release of GABA, which results in a disinhibition of the dopaminergic VTA neurons. In turn, this is likely to result in an increase in dopamine release in the ventral striatum. In principle, benzodiazepines are likely to have functionally opposing actions via the α1-containing GABA A receptors on GABAergic neurons and on α3-containing GABA A receptors on the dopaminergic neurons of the VTA. However, the effect on the α1-containing GABA A receptors on the dopaminergic neuron is functionally predominant.
Schizophrenia. Benzodiazepines are frequently used as adjunctive treatment to neuroleptics in patients with schizophrenia, although convincing evidence that their use has long-term antipsychotic or cognitive benefits is lacking.
α3 knockout mice and α5(H105R) partial knockout mice with a reduced expression of the α5 subunit display deficits in sensorimotor gating, as determined by prepulse inhibition of acoustic startle, supporting a potential involvement of α3-and α5-containing GABA A receptors in the pathophysiology of schizophrenia 48, 49 . α5 partial knockout mice also display deficits in latent inhibition -that is, retarded conditioning to a stimulus that is repeatedly presented without any reinforcement contingencies 49 . Deficits in this form of learning have also been described in schizophrenia 50 . An important pathophysiological feature in schizophrenia is a hyperactivity of VTA dopaminergic neurons, which express α3-containing GABA A receptors 42, 48 . Moreover, the hippocampus, where α5-containing GABA A receptors are expressed 42 , activates tonic firing of dopaminergic neurons in the midbrain; this circuit involves glutamatergic neurons in the hippocampus, GABAergic neurons in the nucleus accumbens and GABAergic neurons in the ventral pallidum 51, 52 . This framework explains why deficiency of α3-or α5-containing GABA A receptors can lead to increased firing of dopaminergic neurons, highlighting these receptors as potential targets for novel antipsychotic medications. Moreover, because the GABAergic neurons in the ventral pallidum primarily express α1-containing GABA A receptors 42 , one would predict that a compound with activity at α1-containing GABA A receptors might increase firing of dopaminergic neurons and thus that α1 might be a subtype to be avoided when developing an antipsychotic agent.
Interestingly, imidazenil, which has some selectivity for α5-containing GABA A receptors over α1-containing GABA A receptors 53 and is also a partial agonist at α3-containing GABA A receptors 54 , reduces the behavioural deficits in mice that model symptoms of schizophrenia without producing sedation or tolerance liability 53 . The therapeutic potential of positive allosteric modulation of α5-containing GABA A receptors has also been demonstrated in a rat model of schizophrenia that was generated by treatment of pregnant dams on gestational day 17 with the DNA-methylating agent methylazoxymethanol acetate (MAM). In MAM-treated rats, the α5-selective partial agonist SH-053-2′F-R-CH3, administered systemically or locally into the ventral hippocampus, reduced the number of spontaneously active dopaminergic neurons in the VTA to levels observed in saline-treated animals 55 . Moreover, SH-053-2′F-R-CH3 reduced the increased locomotor response of MAMtreated animals to amphetamine 55 . Before the functions of the different GABA A receptor subtypes were known, the non-selective partial agonist and anxiolytic bretazenil was shown to be efficacious as monotherapy in approximately 40% of patients with acute episodes of schizophrenia of moderate to marked severity 56 and devoid of extrapyramidal side effects, indicating that modulators of GABA A receptors can be useful in the treatment of schizophrenia. As sedation is the most frequent adverse event reported (in 21 out of 66 patients) 56 , it is conceivable that a future subtypeselective compound lacking activity at α1-containing GABA A receptors may be useful in the treatment of schizophrenia.
Recent evidence suggests that α2/α3-selective agonists might have therapeutic value for the cognitive impairments of schizophrenia. Altered activation of the dorsolateral prefrontal cortex (DLPFC) has been suggested to be specific to the disease process, leading to the cognitive deficits of schizophrenia. In the cortex and hippocampus, hypofunction of NMDA (N-methyl-daspartate) receptors on GABAergic interneurons, which form synapses with the axon initial segments of cortical pyramidal neurons, results in decreased inhibition of glutamatergic pyramidal neurons 52 . In post-mortem brain from patients with schizophrenia, there is an upregulation of the α2 subunit in the axon initial segments of these pyramidal neurons 57 , which is thought to represent a compensatory adaptation. This provided the rationale for a small clinical trial involving 15 chronic schizophrenic patients with the α2/α3-selective partial agonist TPA023. Some cognitive functions were improved with TPA023 treatment 58 . In addition, EEG recordings revealed increased frontal γ-band power. γ-oscillations are generated by the feedback inhibition mediated by the GABAergic interneurons and abnormalities of γ-oscillations have been proposed to underlie cognitive and negative symptoms of schizophrenia 52 . However, a follow-up study including 60 patients, with some of the same tests, did not confirm these results 59 . However, it should be noted that the efficacy of TPA023 is only 11% at α2-containing GABA A receptors (and 21% at α3-containing GABA A receptors) compared with the full agonist chlordiazepoxide 28 , and thus compounds with higher efficacy at the α2-containing GABA A receptors might elicit stronger and more consistent effects. Further studies with such compounds are required to validate the usefulness of an α2/α3-selective agonist for the treatment of cognitive dysfunction in schizophrenia. It is interesting to note that TPA023 reversed ketamineinduced impairments in spatial working memory in rhesus monkeys but not the ketamine-induced hallucinatory-like behaviours, emphasizing the functional specificity of this approach 60 .
Depression. Currently available antidepressant medications act on the serotonergic and/or noradrenergic systems, but the response rate (defined as >50% decrease in depression severity from baseline) is only approximately 60% 61 . Additionally, these drugs can take weeks or months to develop their antidepressant actions. Therefore, there is an urgent medical need for novel and faster-acting antidepressants. Although there is tremendous interest in developing antidepressant agents that utilize different mechanisms of action, the development of such agents has not yet been successful 62 .
Recently, a GABAergic hypothesis of depression was proposed that posits a central role of the GABA system in the pathophysiology of depression 63 . Moreover, clinical studies have revealed that the benzodiazepines alprazolam and adinazolam elicit antidepressant responses that are similar to those elicited by widely prescribed antidepressants in patients with major depressive disorder 64, 65 ; the receptor subtype (or subtypes) mediating these responses is, however, unknown. In addition, heterozygous γ2 (Gabrg2) knockout mice display an anxiety-like phenotype in tests of unconditioned anxiety 66 and a depressive-like phenotype in conflict-and despair-based tests 67 . These mice also have elevated baseline cortico-sterone concentrations 68 , a feature of major depression in humans. As the γ2 subunit is associated with all known α subunits (α1 to α6), these studies do not indicate which GABA A receptor subtype (or subtypes) is responsible for the depressive-like phenotype in these mice.
As mentioned previously, the α2-containing GABA A receptors have been linked to anxiolysis, and given the high comorbidity between anxiety and depression, it is likely that α2-containing GABA A receptors might also be involved in mood regulation. Indeed, α2 knockout mice display increased anxiety and depression-like behaviour in the conflict-based novelty-suppressed feeding test, and increased depression-like behaviour in the despair-based forced swim and tail suspension tests 69 . These results point to a physiological antidepressant-like role of α2-containing GABA A receptors, suggesting that α2-containing GABA A receptors might also be a valid target for novel non-monoamine-based antidepressant drugs.
Cognitive enhancement. Several studies in animals and humans have suggested that classical benzodiazepines can impair learning and memory [70] [71] [72] . This raises the question of whether negative allosteric modulators (inverse agonists) at the BZ site of GABA A receptors (that is, compounds that inhibit GABA-induced chloride influx) might have cognition-enhancing actions. Nonselective inverse agonists have various unwanted effects, including anxiogenesis and proconvulsant or convulsant activity. Thus, only subtype-selective compounds avoiding such actions may be suitable as cognition enhancers. α5-containing GABA A receptors are predominantly expressed in the hippocampus (where they make up approximately 20% of all GABA A receptors 73 ), and as this region is important for learning and memory, the role of these receptors in cognition has been investigated using mutant mice and subtype-selective ligands.
In the hippocampus, α5-containing GABA A receptors do not colocalize with the postsynaptic marker gephyrin 14 (and are therefore extrasynaptic (see also BOX 1)) and mediate both tonic and slow phasic inhibition 74, 75 , which modulate cognitive functions. In α5(H105R) partial knockout mice, the results of delay fear conditioning -a hippocampal-independent task in which a tone is immediately followed by an electric shock or co-terminates with a shock -are similar to the results from wildtype mice. However, α5(H105R) partial knockout mice show improved trace fear conditioning -a hippocampaldependent task in which the tone and shock are separated in time (for example, by 1 s or 30 s) -compared with wild-type mice 14, 76 . The separation in time of tone and shock usually decreases the response, but this is not the case in the α5(H105R) partial knockout mice 14, 76 (FIG. 2b) , although the latter compound has a very low efficacy at α5-containing receptors. RO4938581 reversed scopolamine-induced working memory impairment and increased performance in the Morris water maze 78 . L-655708 also enhanced performance in the Morris water maze during acquisition and in a probe trial 80 . Interestingly, α5IA (FIG. 2b) , a functionally selective compound, was able to reverse memory deficits induced by alcohol consumption in a small study involving human volunteers 81 without showing signs of anxiogenesis. This is in line with the hypothesis that a compound selective for α5-containing GABA A receptors might also improve cognition in a clinically impaired population (for example, in patients with Alzheimer's disease). However, the development of this compound was stopped owing to a metabolite that produced renal toxicity, which precluded α5IA from being administered to humans over prolonged periods of time 82 . MRK-016 (FIG. 2b) , another functionally selective clinical candidate, acted as a cognition enhancer without convulsant or proconvulsant and anxiogenic effects in animals 83 . Unfortunately, development of this compound was stopped owing to poor tolerability in healthy normal elderly volunteers. A further delineation of the role of α5-containing GABA A receptors in cognitive processes in humans is needed. Importantly, none of these α5-containing receptor selective drugs displays the convulsant and anxiogenic activities of the non-selective GABA A receptor inverse agonists FG-7142, DMCM (methyl-6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate) or β-CCM (methyl β-carboline-3-carboxylate), which are not used therapeutically 10, 84 . A recent study using α5(H105R) partial knockout mice found that α5-containing GABA A receptors are involved in processing memory for the location of objects 85 ; this might indicate that α5 inverse agonists could potentially negatively affect some cognitive functions.
Stroke.
A recent study examined a role for tonic inhibition mediated by extrasynaptic GABA A receptors in stroke 86 . A focal cortical stroke was induced in mouse brain and neuronal excitability in the peri-infarct zone was measured electrophysiologically. The tonic neuronal inhibition was increased, which could be due to an impaired function of GABA transporter 3 (GAT3) and GAT4. In mice treated with the α5-selective inverse agonist L-655708, which reduces tonic inhibition, or in mice lacking α5-or δ-GABA A receptor subunits, the post-stroke recovery of motor function was improved. The best outcomes were obtained when the drug was administered 3 days after stroke. This result may provide new pharmacological targets for recovery from stroke in humans. Although it still has to be demonstrated in humans whether α5-selective inverse agonists can improve post-stroke recovery, the fact that in preclinical studies the drug was effective even 3 days after stroke is particularly noteworthy, as this may indicate that such drug treatment might work even in a delayed time frame when options for early interventions have been missed.
Conclusion and future directions
The identification of physiological and pharmacological functions of GABA A receptor subtypes defined by their α subunits has renewed the interest in the GABA A receptor system as a target for the development of drugs with fewer side effects than classical benzodiazepines (for example, non-sedating anxiolytics) and the development of drugs with indications that are distinct from those of classical benzodiazepines (for example, analgesics and cognition-enhancing drugs). A significant number of compounds have now been developed that display GABA A receptor subtype selectivity by affinity or efficacy, or by both (TABLE 1) . In animal models, subtypeselective drugs do not lose their efficacy for the desired actions, and separation of desired from adverse effects can readily be achieved. The example of MRK-409 -a compound that reached clinical studies but whose development had to be stopped owing to sedative effects in humans -demonstrates that more preclinical efforts are needed to identify compounds with improved selectivity. This may be primarily achieved with higher affinity only at the desired receptor subtype. In addition to the development of non-sedative anxiolytics and cognitionenhancing drugs, recent scientific discoveries provide hope for the development of analgesic drugs for the treatment of chronic pain. 
